Abstract
Opioid analgesics have long been accepted by the medical community for the treatment of acute, surgical and cancer-related pain; only recently have opioids become more widely used in the treatment of chronic pain conditions. Studies have demonstrated that opioids can be effective in the treatment of chronic pain in some individuals. However, there are certain risks associated with the long-term use of opioid analgesics. The prescribing clinician must consider not only common side effect profile of these medications, but also the unique side effects associated with long-term opioid administration and the risk of addiction. The risks and benefits of prescribing opioids must be carefully weighed for each chronic pain patient. The following chapter provides a discussion of the risks and benefits of using opioid analgesics in the treatment of chronic pain. Potential problems associated with opioid therapy are addressed, and various strategies to manage these problems are also included.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abs, R., Verhelst, J., Maeyaert, J., Van Buyten, J. P., Opsomer, F., et al. (2000). Endocrine consequences of long-term intrathecal administration of opioids. The Journal of Clinical Endocrinology and Metabolism, 85, 2215–2222.
Amabile, C. M., & Bowman, B. J. (2006). Overview of oral modified-release opioid products for the management of chronic pain. The Annals of Pharmacotherapy, 40, 1327–1335.
American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association.
American Psychiatric Association. (2011). DSM-5 development proposed revisions: Substance-related disorders. Washington, DC: American Psychiatric Association.
Apkarian, A. V., Sosa, Y., Sonty, S., Levy, R. M., Harden, R. N., et al. (2004). Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. The Journal of Neuroscience, 24, 10410–10415.
Arner, S., & Meyerson, B. A. (1988). Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain, 33, 11–23.
Arnold, L. M., Hudson, J. I., Hess, E. V., Ware, A. E., Fritz, D. A., et al. (2004). Family study of fibromyalgia. Arthritis and Rheumatism, 50, 944–952.
Askitopoulou, H., Ramoutsaki, I. A., & Konsolaki, E. (2002). Archaeological evidence on the use of opium in the Minoan world. International Congress Series, 1292, 23–97.
Asmundson, G. J., Coons, M. J., Taylor, S., & Katz, J. (2002). PTSD and the experience of pain: Research and clinical implications of shared vulnerability and mutual maintenance models. Canadian Journal of Psychiatry, 47, 930–937.
Asmundson, G. J., & Katz, J. (2009). Understanding the co-occurrence of anxiety disorders and chronic pain: State-of-the-art. Depression and Anxiety, 26, 888–901.
Baile, C. A., McLaughlin, C. L., & Della-Fera, M. A. (1986). Role of cholecystokinin and opioid peptides in control of food intake. Physiological Reviews, 66, 172–234.
Bailey, C. J., & Flatt, P. R. (1987). Increased responsiveness to glucoregulatory effect of opiates in obese-diabetic ob/ob mice. Diabetologia, 30, 33–37.
Baliki, M. N., Chialvo, D. R., Geha, P. Y., Levy, R. M., Harden, R. N., et al. (2006). Chronic pain and the emotional brain: Specific brain activity associated with spontaneous fluctuations of intensity of chronic back pain. The Journal of Neuroscience, 26, 12165–12173.
Baliki, M. N., Geha, P. Y., Apkarian, A. V., & Chialvo, D. R. (2008). Beyond feeling: Chronic pain hurts the brain, disrupting the default-mode network dynamics. The Journal of Neuroscience, 28, 1398–1403.
Ballantyne, J. C. (2007). Opioid analgesia: Perspectives on right use and utility. Pain Physician, 10, 479–491.
Beaver, W. T., Wallenstein, S. L., Houde, R. W., & Rogers, A. (1967). A clinical comparison of the analgesic effects of methadone and morphine administered intramuscularly, and of orally and parenterally administered methadone. Clinical Pharmacology and Therapeutics, 8, 415–426.
Bederson, J. B., Fields, H. L., & Barbaro, N. M. (1990). Hyperalgesia during naloxone-precipitated withdrawal from morphine is associated with increased on-cell activity in the rostral ventromedial medulla. Somatosensory and Motor Research, 7, 185–203.
Belgrade, M. J., Schamber, C. D., & Lindgren, B. R. (2006). The DIRE score: Predicting outcomes of opioid prescribing for chronic pain. The Journal of Pain, 7, 671–681.
Bliesener, N., Albrecht, S., Schwager, A., Weckbecker, K., Lichtermann, D., et al. (2005). Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. The Journal of Clinical Endocrinology and Metabolism, 90, 203–206.
Bloodworth, D. (2005). Issues in opioid management. American Journal of Physical Medicine & Rehabilitation, 84, S42–S55.
Booth, M. (1986). Opium: A history. New York, NY: St. Martin’s Press.
Buckalew, N., Haut, M. W., Aizenstein, H., Morrow, L., Perera, S., et al. (2010). Differences in brain structure and function in older adults with self-reported disabling and nondisabling chronic low back pain. Pain Medicine, 11, 1183–1197.
Butler, S. F., Budman, S. H., Fernandez, K. C., Houle, B., Benoit, C., et al. (2007). Development and validation of the Current Opioid Misuse Measure. Pain, 130, 144–156.
Butler, S. F., Fernandez, K., Benoit, C., Budman, S. H., & Jamison, R. N. (2008). Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). The Journal of Pain, 9, 360–372.
Caldwell, J. R., Hale, M. E., Boyd, R. E., Hague, J. M., Iwan, T., et al. (1999). Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: A double blind, randomized, multicenter, placebo controlled trial. The Journal of Rheumatology, 26, 862–869.
Caldwell, J. R., Rapoport, R. J., Davis, J. C., Offenberg, H. L., Marker, H. W., et al. (2002). Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: Results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. Journal of Pain and Symptom Management, 23, 278–291.
Caudill-Slosberg, M. A., Schwartz, L. M., & Woloshin, S. (2004). Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain, 109, 514–519.
Celerier, E., Rivat, C., Jun, Y., Laulin, J. P., Larcher, A., et al. (2000). Long-lasting hyperalgesia induced by fentanyl in rats: Preventive effect of ketamine. Anesthesiology, 92, 465–472.
Chabal, C., Erjavec, M. K., Jacobson, L., Mariano, A., & Chaney, E. (1997). Prescription opiate abuse in chronic pain patients: Clinical criteria, incidence, and predictors. The Clinical Journal of Pain, 13, 150–155.
Chang, G., Chen, L., & Mao, J. (2007). Opioid tolerance and hyperalgesia. The Medical Clinics of North America, 91, 199–211.
Chapman, C. R., Lipschitz, D. L., Angst, M. S., Chou, R., Denisco, R. C., et al. (2010). Opioid pharmacotherapy for chronic non-cancer pain in the United States: A research guideline for developing an evidence-base. The Journal of Pain, 11, 807–829.
Chiou, L. C., Liao, Y. Y., Fan, P. C., Kuo, P. H., Wang, C. H., et al. (2007). Nociceptin/orphanin FQ peptide receptors: Pharmacology and clinical implications. Current Drug Targets, 8, 117–135.
Chou, R., Fanciullo, G. J., Fine, P. G., Adler, J. A., Ballantyne, J. C., et al. (2009). Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. The Journal of Pain, 10, 113–130.
Christie, M. J. (2008). Cellular neuroadaptations to chronic opioids: Tolerance, withdrawal and addiction. British Journal of Pharmacology, 154, 384–396.
Chu, L. F., Clark, D. J., & Angst, M. S. (2006). Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: A preliminary prospective study. The Journal of Pain, 7, 43–48.
Chugh, S. S., Socoteanu, C., Reinier, K., Waltz, J., Jui, J., et al. (2008). A community-based evaluation of sudden death associated with therapeutic levels of methadone. The American Journal of Medicine, 121, 66–71.
Compton, P., Charuvastra, V. C., & Ling, W. (2001). Pain intolerance in opioid-maintained former opiate addicts: Effect of long-acting maintenance agent. Drug and Alcohol Dependence, 63, 139–146.
Compton, P., Darakjian, J., & Miotto, K. (1998). Screening for addiction in patients with chronic pain and “problematic” substance use: Evaluation of a pilot assessment tool. Journal of Pain and Symptom Management, 16, 355–363.
Cook, R. F., Bernstein, A. D., Arrington, T. L., Andrews, C. M., & Marshall, G. A. (1995). Methods for assessing drug use prevalence in the workplace: A comparison of self-report, urinalysis, and hair analysis. The International Journal of the Addictions, 30, 403–426.
Cowan, D. T., Wilson-Barnett, J., Griffiths, P., Vaughan, D. J., Gondhia, A., et al. (2005). A randomized, double-blind, placebo-controlled, cross-over pilot study to assess the effects of long-term opioid drug consumption and subsequent abstinence in chronic noncancer pain patients receiving controlled-release morphine. Pain Medicine, 6, 113–121.
Cruciani, R. A., Sekine, R., Homel, P., Lussier, D., Yap, Y., et al. (2005). Measurement of QTc in patients receiving chronic methadone therapy. Journal of Pain and Symptom Management, 29, 385–391.
Daniell, H. W. (2002). Hypogonadism in men consuming sustained-action oral opioids. The Journal of Pain, 3, 377–384.
Daniell, H. W. (2008). Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. The Journal of Pain, 9, 28–36.
Daniell, H. W., Lentz, R., & Mazer, N. A. (2006). Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency. The Journal of Pain, 7, 200–210.
Dellemijn, P. L., & Vanneste, J. A. (1997). Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet, 349, 753–758.
Devulder, J., Richarz, U., & Nataraja, S. H. (2005). Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Current Medical Research and Opinion, 21, 1555–1568.
Dikotter, F., Laaman, L., & Xun, Z. (2004). Narcotic culture: A history of drugs in China. Chicago, IL: University of Chicago Press.
Dogrul, A., Bilsky, E. J., Ossipov, M. H., Lai, J., & Porreca, F. (2005). Spinal L-type calcium channel blockade abolishes opioid-induced sensory hypersensitivity and antinociceptive tolerance. Anesthesia and Analgesia, 101, 1730–1735.
Dohrenwend, B. P., Raphael, K. G., Marbach, J. J., & Gallagher, R. M. (1999). Why is depression comorbid with chronic myofascial face pain? A family study test of alternative hypotheses. Pain, 83, 183–192.
Edlund, M. J., Steffick, D., Hudson, T., Harris, K. M., & Sullivan, M. (2007). Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain, 129, 355–362.
Eisendrath, S. J. (1995). Psychiatric aspects of chronic pain. Neurology, 45, S26–S34; discussion S35–S36.
Elander, J., Lusher, J., Bevan, D., Telfer, P., & Burton, B. (2004). Understanding the causes of problematic pain management in sickle cell disease: Evidence that pseudoaddiction plays a more important role than genuine analgesic dependence. Journal of Pain and Symptom Management, 27, 156–169.
Elliott, A. M., Smith, B. H., Penny, K. I., Smith, W. C., & Chambers, W. A. (1999). The epidemiology of chronic pain in the community. Lancet, 354, 1248–1252.
Epstein, D. H., Preston, K. L., & Jasinski, D. R. (2006). Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: Lessons from tramadol. Biological Psychology, 73, 90–99.
Fishbain, D. A. (1999). Approaches to treatment decisions for psychiatric comorbidity in the management of the chronic pain patient. Medical Clinics of North America, 83, 737–760, vii.
Fishbain, D. A., Cole, B., Lewis, J. E., Gao, J., & Rosomoff, R. S. (2009). Do opioids induce hyperalgesia in humans? An evidence-based structured review. Pain Medicine, 10, 829–839.
Fishbain, D. A., Cutler, R. B., Rosomoff, H. L., & Rosomoff, R. S. (1999). Validity of self-reported drug use in chronic pain patients. The Clinical Journal of Pain, 15, 184–191.
Fishbain, D. A., Rosomoff, H. L., & Rosomoff, R. S. (1992). Drug abuse, dependence, and addiction in chronic pain patients. The Clinical Journal of Pain, 8, 77–85.
Fleming, M. F., Davis, J., & Passik, S. D. (2008). Reported lifetime aberrant drug-taking behaviors are predictive of current substance use and mental health problems in primary care patients. Pain Medicine, 9, 1098–1106.
Flor, H., Fydrich, T., & Turk, D. C. (1992). Efficacy of multidisciplinary pain treatment centers: A meta-analytic review. Pain, 49, 221–230.
Foley, K. M., & Houde, R. W. (1998). Methadone in cancer pain management: Individualize dose and titrate to effect. Journal of Clinical Oncology, 16, 3213–3215.
Fraser, L. A., Morrison, D., Morley-Forster, P., Paul, T. L., Tokmakejian, S., et al. (2009). Oral opioids for chronic non-cancer pain: Higher prevalence of hypogonadism in men than in women. Experimental and Clinical Endocrinology & Diabetes, 117, 38–43.
Fredheim, O. M., Borchgrevink, P. C., Hegrenaes, L., Kaasa, S., Dale, O., et al. (2006a). Opioid switching from morphine to methadone causes a minor but not clinically significant increase in QTc time: A prospective 9-month follow-up study. Journal of Pain and Symptom Management, 32, 180–185.
Fredheim, O. M., Kaasa, S., Dale, O., Klepstad, P., Landro, N. I., et al. (2006b). Opioid switching from oral slow release morphine to oral methadone may improve pain control in chronic non-malignant pain: A nine-month follow-up study. Palliative Medicine, 20, 35–41.
Freye, E., Anderson-Hillemacher, A., Ritzdorf, I., & Levy, J. V. (2007). Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Pain Practice, 7, 123–129.
Furlan, A. D., Sandoval, J. A., Mailis-Gagnon, A., & Tunks, E. (2006). Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects. The Canadian Medical Association Journal, 174, 1589–1594.
Gagajewski, A., & Apple, F. S. (2003). Methadone-related deaths in Hennepin County, Minnesota: 1992–2002. Journal of Forensic Sciences, 48, 668–671.
Galer, B. S., Coyle, N., Pasternak, G. W., & Portenoy, R. K. (1992). Individual variability in the response to different opioids: Report of five cases. Pain, 49, 87–91.
Gallagher, R. M. (2004). Biopsychosocial pain medicine and mind-brain-body science. Physical Medicine and Rehabilitation Clinics of North America, 15, 855–882, vii.
Gallagher, R. M., Marbach, J. J., Raphael, K. G., Handte, J., & Dohrenwend, B. P. (1995). Myofascial face pain: Seasonal variability in pain intensity and demoralization. Pain, 61, 113–120.
Gallagher, R. M., & Rosenthal, L. J. (2008). Chronic pain and opiates: Balancing pain control and risks in long-term opioid treatment. Archives of Physical Medicine and Rehabilitation, 89, S77–S82.
Gallagher, R. M., & Verma, S. (1999). Managing pain and comorbid depression: A public health challenge. Seminars in Clinical Neuropsychiatry, 4, 203–220.
Gallagher, R. M., Verma, S., & Mossey, J. (2000). Chronic pain. Sources of late-life pain and risk factors for disability. Geriatrics, 55, 40–44, 47.
Gardell, L. R., Wang, R., Burgess, S. E., Ossipov, M. H., Vanderah, T. W., et al. (2002). Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. The Journal of Neuroscience, 22, 6747–6755.
Gatti, A., Reale, C., Luzi, M., Canneti, A., Mediati, R. D., et al. (2010). Effects of opioid rotation in chronic pain patients: ORTIBARN study. Clinical Drug Investigation, 30(Suppl 2), 39–47.
Geisser, M. E., Robinson, M. E., Miller, Q. L., & Bade, S. M. (2003). Psychosocial factors and functional capacity evaluation among persons with chronic pain. Journal of Occupational Rehabilitation, 13, 259–276.
Giesecke, T., Gracely, R. H., Williams, D. A., Geisser, M. E., Petzke, F. W., et al. (2005). The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis and Rheumatism, 52, 1577–1584.
Gillen, C., Haurand, M., Kobelt, D. J., & Wnendt, S. (2000). Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn-Schmiedeberg’s Archives of Pharmacology, 362, 116–121.
Gimbel, J. S., Richards, P., & Portenoy, R. K. (2003). Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial. Neurology, 60, 927–934.
Giugliano, D. (1984). Morphine, opioid peptides, and pancreatic islet function. Diabetes Care, 7, 92–98.
Gomez-Flores, R., & Weber, R. J. (2000). Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaqueductal gray. Immunopharmacology, 48, 145–156.
Gonzalez-Barboteo, J., Porta-Sales, J., Sanchez, D., Tuca, A., & Gomez-Batiste, X. (2008). Conversion from parenteral to oral methadone. Journal of Pain & Palliative Care Pharmacotherapy, 22, 200–205.
Gordon, D. B., Dahl, J., Phillips, P., Frandsen, J., Cowley, C., et al. (2004). The use of “as-needed” range orders for opioid analgesics in the management of acute pain: A consensus statement of the American Society for Pain Management Nursing and the American Pain Society. Pain Management Nursing, 5, 53–58.
Gourlay, D. L., Heit, H. A., & Almahrezi, A. (2005). Universal precautions in pain medicine: A rational approach to the treatment of chronic pain. Pain Medicine, 6, 107–112.
Griessinger, N., Sittl, R., & Likar, R. (2005). Transdermal buprenorphine in clinical practice – A post-marketing surveillance study in 13,179 patients. Current Medical Research and Opinion, 21, 1147–1156.
Grond, S., & Sablotzki, A. (2004). Clinical pharmacology of tramadol. Clinical Pharmacokinetics, 43, 879–923.
Guignard, B., Bossard, A. E., Coste, C., Sessler, D. I., Lebrault, C., et al. (2000). Acute opioid tolerance: Intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology, 93, 409–417.
Guststein, H. B., & Akil, H. (2006). Opioid analgesics. In L. L. Brunton, J. S. Lazo, & K. L. Parker (Eds.), Goodman and Gilman’s the pharmacological basis of therapeutics (11th ed., pp. 547–590). New York, NY: McGraw-Hill Medical.
Guzman, J., Esmail, R., Karjalainen, K., Malmivaara, A., Irvin, E., et al. (2001). Multidisciplinary rehabilitation for chronic low back pain: Systematic review. British Medical Journal, 322, 1511–1516.
Hallinan, R., Byrne, A., Agho, K., McMahon, C., Tynan, P., et al. (2008). Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. The Journal of Sexual Medicine, 5, 684–692.
Han, W., Ide, S., Sora, I., Yamamoto, H., & Ikeda, K. (2004). A possible genetic mechanism underlying individual and interstrain differences in opioid actions: Focus on the mu opioid receptor gene. Annals of the New York Academy of Sciences, 1025, 370–375.
Heit, H. A., & Gourlay, D. L. (2008). Buprenorphine: New tricks with an old molecule for pain management. The Clinical Journal of Pain, 24, 93–97.
Hoffman, B. M., Papas, R. K., Chatkoff, D. K., & Kerns, R. D. (2007). Meta-analysis of psychological interventions for chronic low back pain. Health Psychology, 26, 1–9.
Inturrisi, C. E. (2002). Clinical pharmacology of opioids for pain. The Clinical Journal of Pain, 18, S3–S13.
Ives, T. J., Chelminski, P. R., Hammett-Stabler, C. A., Malone, R. M., Perhac, J. S., et al. (2006). Predictors of opioid misuse in patients with chronic pain: A prospective cohort study. BMC Health Services Research, 6, 46.
Jamison, R. N., Raymond, S. A., Slawsby, E. A., Nedeljkovic, S. S., & Katz, N. P. (1998). Opioid therapy for chronic noncancer back pain. A randomized prospective study. Spine (Philadelphia, Pa 1976), 23, 2591–2600.
Jovey, R. D., Ennis, J., Gardner-Nix, J., Goldman, B., Hays, H., et al. (2003). Use of opioid analgesics for the treatment of chronic noncancer pain – A consensus statement and guidelines from the Canadian Pain Society, 2002. Pain Research & Management, 8(Suppl A), 3A–28A.
Kalso, E., Edwards, J. E., Moore, R. A., & McQuay, H. J. (2004). Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. Pain, 112, 372–380.
Kanner, R. M., & Foley, K. M. (1981). Patterns of narcotic drug use in a cancer pain clinic. Annals of the New York Academy of Sciences, 362, 161–172.
Kaplan, H., & Fields, H. L. (1991). Hyperalgesia during acute opioid abstinence: Evidence for a nociceptive facilitating function of the rostral ventromedial medulla. The Journal of Neuroscience, 11, 1433–1439.
Karam, G. A., Reisi, M., Kaseb, A. A., Khaksari, M., Mohammadi, A., et al. (2004). Effects of opium addiction on some serum factors in addicts with non-insulin-dependent diabetes mellitus. Addiction Biology, 9, 53–58.
Karci, A., Tasdogen, A., Erkin, Y., Aktas, G., & Elar, Z. (2004). The analgesic effect of morphine on postoperative pain in diabetic patients. Acta Anaesthesiologica Scandinavica, 48, 619–624.
Katz, N., & Fanciullo, G. J. (2002). Role of urine toxicology testing in the management of chronic opioid therapy. The Clinical Journal of Pain, 18, S76–S82.
Katz, N. P., Sherburne, S., Beach, M., Rose, R. J., Vielguth, J., et al. (2003). Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesthesia and Analgesia, 97, 1097–1102, table of contents.
King, T., Gardell, L. R., Wang, R., Vardanyan, A., Ossipov, M. H., et al. (2005). Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain, 116, 276–288.
Kinjo, M., Setoguchi, S., Schneeweiss, S., & Solomon, D. H. (2005). Bone mineral density in subjects using central nervous system-active medications. The American Journal of Medicine, 118, 1414.
Koch, T., & Hollt, V. (2008). Role of receptor internalization in opioid tolerance and dependence. Pharmacology and Therapeutics, 117, 199–206.
Krantz, M. J., Lewkowiez, L., Hays, H., Woodroffe, M. A., Robertson, A. D., et al. (2002). Torsade de pointes associated with very-high-dose methadone. Annals of Internal Medicine, 137, 501–504.
Kreek, M. J. (2001). Drug addictions. Molecular and cellular endpoints. Annals of the New York Academy of Sciences, 937, 27–49.
Kulkarni, B., Bentley, D. E., Elliott, R., Julyan, P. J., Boger, E., et al. (2007). Arthritic pain is processed in brain areas concerned with emotions and fear. Arthritis and Rheumatism, 56, 1345–1354.
Lafisca, S., Bolelli, G., Franceschetti, F., Danieli, A., Tagliaro, F., et al. (1985). Free and bound testosterone in male heroin addicts. Archives of Toxicology Supplement, 8, 394–397.
Langleben, D. D., Ruparel, K., Elman, I., Busch-Winokur, S., Pratiwadi, R., et al. (2008). Acute effect of methadone maintenance dose on brain FMRI response to heroin-related cues. The American Journal of Psychiatry, 165, 390–394.
Laulin, J. P., Maurette, P., Corcuff, J. B., Rivat, C., Chauvin, M., et al. (2002). The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance. Anesthesia and Analgesia, 94, 1263–1269, table of contents.
Leo, J. A., Tanga, F. Y., & Tawfik, V. L. (2004). Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscentist, 10, 40–52.
Levine, A. S., Morley, J. E., Gosnell, B. A., Billington, C. J., & Bartness, T. J. (1985). Opioids and consummatory behavior. Brain Research Bulletin, 14, 663–672.
Lidstone, S. C., & Stoessl, A. J. (2007). Understanding the placebo effect: Contributions from neuroimaging. Molecular Imaging and Biology, 9, 176–185.
Lusher, J., Elander, J., Bevan, D., Telfer, P., & Burton, B. (2006). Analgesic addiction and pseudoaddiction in painful chronic illness. The Clinical Journal of Pain, 22, 316–324.
Lynch, M. E. (2005). A review of the use of methadone for the treatment of chronic noncancer pain. Pain Research & Management, 10, 133–144.
Manchikanti, L., Cash, K. A., Damron, K. S., Manchukonda, R., Pampati, V., et al. (2006). Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of multiple variables. Pain Physician, 9, 215–225.
Mao, J. (2002). Opioid-induced abnormal pain sensitivity: Implications in clinical opioid therapy. Pain, 100, 213–217.
Mao, J. (2006). Opioid-induced abnormal pain sensitivity. Current Pain and Headache Reports, 10, 67–70.
Mao, J., Price, D. D., & Mayer, D. J. (1994). Thermal hyperalgesia in association with the development of morphine tolerance in rats: Roles of excitatory amino acid receptors and protein kinase C. The Journal of Neuroscience, 14, 2301–2312.
Martin, B. I., Deyo, R. A., Mirza, S. K., Turner, J. A., Comstock, B. A., et al. (2008). Expenditures and health status among adults with back and neck problems. The Journal of American Medical Association, 299, 656–664.
Martucci, C., Panerai, A. E., & Sacerdote, P. (2004). Chronic fentanyl or buprenorphine infusion in the mouse: Similar analgesic profile but different effects on immune responses. Pain, 110, 385–392.
Maxwell, J. C., Pullum, T. W., & Tannert, K. (2005). Deaths of clients in methadone treatment in Texas: 1994–2002. Drug and Alcohol Dependence, 78, 73–81.
McNicol, E., Horowicz-Mehler, N., Fisk, R. A., Bennett, K., Gialeli-Goudas, M., et al. (2003). Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review. The Journal of Pain, 4, 231–256.
McQuay, H. (1999). Opioids in pain management. Lancet, 353, 2229–2232.
McWilliams, L. A., Clara, I. P., Murphy, P. D., Cox, B. J., & Sareen, J. (2008). Associations between arthritis and a broad range of psychiatric disorders: Findings from a nationally representative sample. The Journal of Pain, 9, 37–44.
Meghani, S. H., Wiedemer, N. L., Becker, W. C., Gracely, E. J., & Gallagher, R. M. (2009). Predictors of resolution of aberrant drug behavior in chronic pain patients treated in a structured opioid risk management program. Pain Medicine, 10, 858–865.
Meldrum, M. L. (2003). A capsule history of pain management. The Journal of American Medical Association, 290, 2470–2475.
Meunier, J. C., Mollereau, C., Toll, L., Suaudeau, C., Moisand, C., et al. (1995). Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature, 377, 532–535.
Michna, E., Ross, E. L., Hynes, W. L., Nedeljkovic, S. S., Soumekh, S., et al. (2004). Predicting aberrant drug behavior in patients treated for chronic pain: Importance of abuse history. Journal of Pain and Symptom Management, 28, 250–258.
Moore, R. A., & McQuay, H. J. (2005). Prevalence of opioid adverse events in chronic non-malignant pain: Systematic review of randomised trials of oral opioids. Arthritis Research & Therapy, 7, R1046–R1051.
Morley, S., Eccleston, C., & Williams, A. (1999). Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. Pain, 80, 1–13.
Mossey, J. M., & Gallagher, R. M. (2004). The longitudinal occurrence and impact of comorbid chronic pain and chronic depression over two years in continuing care retirement community residents. Pain Medicine, 5, 335–348.
Moulin, D. E., Iezzi, A., Amireh, R., Sharpe, W. K., Boyd, D., et al. (1996). Randomised trial of oral morphine for chronic non-cancer pain. Lancet, 347, 143–147.
Nicholas, M. K., Molloy, A. R., & Brooker, C. (2006). Using opioids with persisting noncancer pain: A biopsychosocial perspective. The Clinical Journal of Pain, 22, 137–146.
Nickel, M. K., Lahmann, C., Muehlbacher, M., Nickel, C., Pedrosa Gil, F., et al. (2006). Change in instrumental activities of daily living disability in female senior patients with musculosceletal pain: A prospective, randomized, controlled trial. Archives of Gerontology and Geriatrics, 42, 247–255.
O’Brien, C. P. (Ed.). (2006). Drug addiction and drug abuse (11th ed., pp. 607–625). New York, NY: McGraw-Hill.
Office of Applied Studies SAaMHSA. (2005). Results from the 2004 national survey on drug use and health. Rockville, MD: Department of Health and Human Services.
Ohtani, M., Kotaki, H., Nishitateno, K., Sawada, Y., & Iga, T. (1997). Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. The Journal of Pharmacology and Experimental Therapeutics, 281, 428–433.
Ohtani, M., Kotaki, H., Sawada, Y., & Iga, T. (1995). Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. The Journal of Pharmacology and Experimental Therapeutics, 272, 505–510.
Olsen, Y., Daumit, G. L., & Ford, D. E. (2006). Opioid prescriptions by U.S. primary care physicians from 1992 to 2001. The Journal of Pain, 7, 225–235.
Olsen, G. D., Wendel, H. A., Livermore, J. D., Leger, R. M., Lynn, R. K., et al. (1977). Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. Clinical Pharmacology and Therapeutics, 21, 147–157.
Paice, J. A., Penn, R. D., & Ryan, W. G. (1994). Altered sexual function and decreased testosterone in patients receiving intraspinal opioids. Journal of Pain and Symptom Management, 9, 126–131.
Pain IAftSo. (1986). Classification of chronic pain: Descriptions of chronic pain syndromes and definitions of pain terms. International Association for the Study of Pain, Subcommittee on Taxonomy. Pain. Supplement, 3, S1–S226.
Pereira, J., Lawlor, P., Vigano, A., Dorgan, M., & Bruera, E. (2001). Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing. Journal of Pain and Symptom Management, 22, 672–687.
Piercefield, E., Archer, P., Kemp, P., & Mallonee, S. (2010). Increase in unintentional medication overdose deaths: Oklahoma, 1994–2006. American Journal of Preventive Medicine, 39, 357–363.
Pincus, T., Burton, A. K., Vogel, S., & Field, A. P. (2002). A systematic review of psychological factors as predictors of chronicity/disability in prospective cohorts of low back pain. Spine (Philadelphia, Pa 1976), 27, E109–E120.
Portenoy, R. K. (1996). Opioid therapy for chronic nonmalignant pain: A review of the critical issues. Journal of Pain and Symptom Management, 11, 203–217.
Portenoy, R. K., & Foley, K. M. (1986). Chronic use of opioid analgesics in non-malignant pain: Report of 38 cases. Pain, 25, 171–186.
Porter, J., & Jick, H. (1980). Addiction rare in patients treated with narcotics. The New England Journal of Medicine, 302, 123.
Raffa, R. B., Friderichs, E., Reimann, W., Shank, R. P., Codd, E. E., et al. (1992). Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. The Journal of Pharmacology and Experimental Therapeutics, 260, 275–285.
Raja, S. N., Haythornthwaite, J. A., Pappagallo, M., Clark, M. R., Travison, T. G., et al. (2002). Opioids versus antidepressants in postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology, 59, 1015–1021.
Ralphs, J. A., Williams, A. C., Richardson, P. H., Pither, C. E., & Nicholas, M. K. (1994). Opiate reduction in chronic pain patients: A comparison of patient-controlled reduction and staff controlled cocktail methods. Pain, 56, 279–288.
Raphael, K. G., Janal, M. N., Nayak, S., Schwartz, J. E., & Gallagher, R. M. (2004). Familial aggregation of depression in fibromyalgia: A community-based test of alternate hypotheses. Pain, 110, 449–460.
Raphael, K. G., Natelson, B. H., Janal, M. N., & Nayak, S. (2002). A community-based survey of fibromyalgia-like pain complaints following the World Trade Center terrorist attacks. Pain, 100, 131–139.
Rasheed, A., & Tareen, I. A. (1995). Effects of heroin on thyroid function, cortisol and testosterone level in addicts. Polish Journal of Pharmacology, 47, 441–444.
Rauck, R. L. (2009). What is the case for prescribing long-acting opioids over short-acting opioids for patients with chronic pain? A critical review. Pain Practice, 9, 468–479.
Reid, M. C., Engles-Horton, L. L., Weber, M. B., Kerns, R. D., Rogers, E. L., et al. (2002). Use of opioid medications for chronic noncancer pain syndromes in primary care. Journal of General Internal Medicine, 17, 173–179.
Reinscheid, R. K., Nothacker, H. P., Bourson, A., Ardati, A., Henningsen, R. A., et al. (1995). Orphanin FQ: A neuropeptide that activates an opioidlike G protein-coupled receptor. Science, 270, 792–794.
Rice, A. S., & Maton, S. (2001). Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study. Pain, 94, 215–224.
Ripamonti, C., Groff, L., Brunelli, C., Polastri, D., Stavrakis, A., et al. (1998). Switching from morphine to oral methadone in treating cancer pain: What is the equianalgesic dose ratio? Journal of Clinical Oncology, 16, 3216–3221.
Risdahl, J. M., Khanna, K. V., Peterson, P. K., & Molitor, T. W. (1998). Opiates and infection. Journal of Neuroimmunology, 83, 4–18.
Rohling, M. L., Binder, L. M., & Langhinrichsen-Rohling, J. (1995). Money matters: A meta-analytic review of the association between financial compensation and the experience and treatment of chronic pain. Health Psychology, 14, 537–547.
Rosenblum, A., Marsch, L. A., Joseph, H., & Portenoy, R. K. (2008). Opioids and the treatment of chronic pain: Controversies, current status, and future directions. Experimental and Clinical Psychopharmacology, 16, 405–416.
Rowbotham, M., Harden, N., Stacey, B., Bernstein, P., & Magnus-Miller, L. (1998). Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. The Journal of American Medical Association, 280, 1837–1842.
Russell, I. J., Kamin, M., Bennett, R. M., Schnitzer, T. J., Green, J. A., et al. (2000). Efficacy of tramadol in treatment of pain in fibromyalgia. Journal of Clinical Rheumatology, 6, 250–257.
Sacerdote, P. (2006). Opioids and the immune system. Palliative Medicine, 20(Suppl 1), s9–s15.
Sacerdote, P., Manfredi, B., Mantegazza, P., & Panerai, A. E. (1997). Antinociceptive and immunosuppressive effects of opiate drugs: A structure-related activity study. British Journal of Pharmacology, 121, 834–840.
Sadava, D., Alonso, D., Hong, H., & Pettit-Barrett, D. P. (1997). Effect of methadone addiction on glucose metabolism in rats. General Pharmacology, 28, 27–29.
Schieffer, B. M., Pham, Q., Labus, J., Baria, A., Van Vort, W., et al. (2005). Pain medication beliefs and medication misuse in chronic pain. The Journal of Pain, 6, 620–629.
Schmitz, R. (1985). Friedrich Wilhelm Serturner and the discovery of morphine. Pharmacy in History, 27, 61–74.
Schnitzer, T. J., Gray, W. L., Paster, R. Z., & Kamin, M. (2000). Efficacy of tramadol in treatment of chronic low back pain. The Journal of Rheumatology, 27, 772–778.
Sell, L. A., Morris, J., Bearn, J., Frackowiak, R. S., Friston, K. J., et al. (1999). Activation of reward circuitry in human opiate addicts. The European Journal of Neuroscience, 11, 1042–1048.
Sindrup, S. H., & Jensen, T. S. (1999). Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain, 83, 389–400.
Skurtveit, S., Furu, K., Bramness, J., Selmer, R., & Tverdal, A. (2010). Benzodiazepines predict use of opioids – A follow-up study of 17,074 men and women. Pain Medicine, 11, 805–814.
Smith, H. S. (2008). Variations in opioid responsiveness. Pain Physician, 11, 237–248.
Smith, H. S., Datta, S., & Manchikanti, L. (2011). Evidence-based pharmacotherapy of chronic pain. In R. J. Moore (Ed.), Handbook of pain and palliative care. New York, NY: Springer.
Stein, C., Reinecke, H., & Sorgatz, H. (2010). Opioid use in chronic noncancer pain: Guidelines revisited. Current Opinion in Anaesthesiology, 23, 598–601.
Stoelting, R. K. (1991). Pharmacology, physiology, & anesthetic practice. Baltimore, MD: Lippincott Williams & Wilkins.
Tennant, F. S., Jr., Rawson, R. A., Miranda, L., & Obert, J. (1983). Outpatient treatment of prescription opioid dependence: Comparison of two methods. NIDA Research Monograph, 43, 315–321.
The American Academy of Pain Medicine tAPS, American Pain Society, and the American Society of Addiction Medicine. (2001). Definitions related to the use of opioids for the treatment of pain.
The Management of Opioid Therapy for Chronic pain Working Group. (2010). VA/DoD clinical practice guideline for management of opioid therapy for chronic pain. Washington, DC: Department of Veteran Affairs.
Tjaderborn, M., Jonsson, A. K., Ahlner, J., & Hagg, S. (2009). Tramadol dependence: A survey of spontaneously reported cases in Sweden. Pharmacoepidemiology and Drug Safety, 18, 1192–1198.
Tracey, I., & Bushnell, M. C. (2009). How neuroimaging studies have challenged us to rethink: Is chronic pain a disease? The Journal of Pain, 10, 1113–1120.
Trescot, A. M. (2010). Review of the role of opioids in cancer pain. Journal of the National Comprehensive Cancer Network, 8, 1087–1094.
Trescot, A. M., Datta, S., Lee, M., & Hansen, H. (2008). Opioid pharmacology. Pain Physician, 11, S133–S153.
Turk, D. C., Swanson, K. S., & Gatchel, R. J. (2008). Predicting opioid misuse by chronic pain patients: A systematic review and literature synthesis. The Clinical Journal of Pain, 24, 497–508.
Twycross, R. G. (1977). A comparison of diamorphine with cocaine and methadone. British Journal of Clinical Pharmacology, 4, 691–693.
Vadivelu, N., & Hines, R. L. (2007). Buprenorphine: A unique opioid with broad clinical applications. Journal of Opioid Management, 3, 49–58.
Vallejo, R., de Leon-Casasola, O., & Benyamin, R. (2004). Opioid therapy and immunosuppression: A review. American Journal of Therapy, 11, 354–365.
van Tulder, M. W., Ostelo, R., Vlaeyen, J. W., Linton, S. J., Morley, S. J., et al. (2000). Behavioral treatment for chronic low back pain: A systematic review within the framework of the Cochrane Back Review Group. Spine (Philadelphia, Pa 1976), 25, 2688–2699.
Vanderah, T. W., Gardell, L. R., Burgess, S. E., Ibrahim, M., Dogrul, A., et al. (2000). Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. The Journal of Neuroscience, 20, 7074–7079.
Vestergaard, P., Rejnmark, L., & Mosekilde, L. (2006). Fracture risk associated with the use of morphine and opiates. Journal of Internal Medicine, 260, 76–87.
Vissers, K. C., Besse, K., Hans, G., Devulder, J., & Morlion, B. (2010). Opioid rotation in the management of chronic pain: Where is the evidence? Pain Practice, 10, 85–93.
Volkow, N., & Li, T. K. (2005). The neuroscience of addiction. Nature Neuroscience, 8, 1429–1430.
Vuong, C., Van Uum, S. H., O’Dell, L. E., Lutfy, K., & Friedman, T. C. (2010). The effects of opioids and opioid analogs on animal and human endocrine systems. Endocrine Reviews, 31, 98–132.
Wasan, A. D., Butler, S. F., Budman, S. H., Fernandez, K., Weiss, R. D., et al. (2009). Does report of craving opioid medication predict aberrant drug behavior among chronic pain patients? The Clinical Journal of Pain, 25, 193–198.
Wasan, A., Michna, E., Greenfield, S., & Jamison, R. (2006). Interpreting urine drug tests: Prevalence of morphine metabolites to hydromorphone in chronic pain patients treated with morphine. Regional Anesthesia and Pain Medicine, 30, A-7.
Wasan, A. D., Wootton, J., & Jamison, R. N. (2005). Dealing with difficult patients in your pain practice. Regional Anesthesia and Pain Medicine, 30, 184–192.
Watkins, L. R., & Maier, S. F. (2000). The pain of being sick: Implications of immune-to-brain communication for understanding pain. Annual Review of Psychology, 51, 29–57.
Watson, C. P., Moulin, D., Watt-Watson, J., Gordon, A., & Eisenhoffer, J. (2003). Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain, 105, 71–78.
Way, B. M., Taylor, S. E., & Eisenberger, N. I. (2009). Variation in the mu-opioid receptor gene (OPRM1) is associated with dispositional and neural sensitivity to social rejection. Proceedings of the National Academy of Sciences of the United States of America, 106, 15079–15084.
Webster, L. R. (2010). Considering the risks of benzodiazepines and opioids together. Pain Medicine, 11, 801–802.
Webster, L. R., Choi, Y., Desai, H., Webster, L., & Grant, B. J. (2008). Sleep-disordered breathing and chronic opioid therapy. Pain Medicine, 9, 425–432.
Webster, L. R., & Webster, R. M. (2005). Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the Opioid Risk Tool. Pain Medicine, 6, 432–442.
Weschules, D. J., & Bain, K. T. (2008). A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Medicine, 9, 595–612.
Wiedemer, N. L., Harden, P. S., Arndt, I. O., & Gallagher, R. M. (2007). The opioid renewal clinic: A primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse. Pain Medicine, 8, 573–584.
Xie, J. Y., Herman, D. S., Stiller, C. O., Gardell, L. R., Ossipov, M. H., et al. (2005). Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance. The Journal of Neuroscience, 25, 409–416.
Yilmaz, B., Konar, V., Kutlu, S., Sandal, S., Canpolat, S., et al. (1999). Influence of chronic morphine exposure on serum LH, FSH, testosterone levels, and body and testicular weights in the developing male rat. Archives of Andrology, 43, 189–196.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Szucs-Reed, R.P., Gallagher, R.M. (2013). Chronic Pain and Opioids. In: Moore, R.J. (eds) Handbook of Pain and Palliative Care. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1651-8_29
Download citation
DOI: https://doi.org/10.1007/978-1-4419-1651-8_29
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-1650-1
Online ISBN: 978-1-4419-1651-8
eBook Packages: MedicineMedicine (R0)